Catalyst Pharmaceuticals Inc (CPRX)

Activity ratios

Short-term

Turnover ratios

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Inventory turnover 12.87 17.80 12.73 11.33 13.69 12.24 10.31 9.77 9.09 9.95 9.24 14.68 13.17 12.40 31.43 25.20 22.09 57.24 94.56 153.74
Receivables turnover 7.44 7.25 7.08 7.68 20.52 20.54 17.78 14.57 21.28 20.16 20.17 21.45 19.89 20.13 17.71 17.20 9.71 7.20 4.03 1.79
Payables turnover 13.60 34.97 30.97 34.51 23.44 34.51 34.95 14.87 25.84 25.13 22.42 25.17 14.40 29.36 9.90 41.34 10.50 8.28 7.67 5.07
Working capital turnover 2.78 2.60 1.61 1.80 0.81 0.83 0.77 0.78 0.77 0.78 0.79 0.82 0.87 0.94 1.08 1.20 1.17 1.00 0.72 0.28

Inventory turnover for Catalyst Pharmaceuticals Inc has been fluctuating over the past years but generally hovers at a moderate level, indicating the company's efficiency in managing its inventory. Receivables turnover has also shown variability but generally reflects the company's ability to collect outstanding receivables efficiently. Payables turnover has been inconsistent, but the company seems to manage its payables effectively, with some periods reflecting faster turnover than others.

The working capital turnover ratio for Catalyst Pharmaceuticals Inc has shown some variability, but overall, the company appears to be utilizing its working capital efficiently to generate revenue. It is important to note that variations in these activity ratios may be influenced by changes in business operations or market conditions and should be analyzed in conjunction with other financial metrics for a comprehensive evaluation of the company's operational efficiency.

Average number of days

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Days of inventory on hand (DOH) days 28.37 20.51 28.66 32.21 26.66 29.82 35.41 37.38 40.17 36.68 39.51 24.86 27.71 29.44 11.61 14.48 16.53 6.38 3.86 2.37
Days of sales outstanding (DSO) days 49.05 50.34 51.56 47.53 17.79 17.77 20.53 25.06 17.15 18.11 18.10 17.02 18.35 18.14 20.61 21.22 37.59 50.70 90.63 204.40
Number of days of payables days 26.83 10.44 11.79 10.58 15.57 10.58 10.44 24.54 14.13 14.52 16.28 14.50 25.35 12.43 36.88 8.83 34.77 44.08 47.59 71.96

The Days of Inventory on Hand (DOH) for Catalyst Pharmaceuticals Inc have shown some fluctuations over the periods analyzed. Recently, the company has been maintaining an average of around 28 days of inventory on hand, indicating that it takes approximately 28 days for the company to sell its inventory. This figure has been relatively stable over the past few quarters, reflecting efficient inventory management.

In terms of Days of Sales Outstanding (DSO), Catalyst Pharmaceuticals Inc has shown a moderate level of collection efficiency. The company takes on average 49 days to collect its accounts receivable. This metric has been fairly consistent in recent quarters, hovering around the 50-day mark. A lower DSO value would indicate faster collection of receivables, thus improving cash flow.

When it comes to the Number of Days of Payables, the company has managed its payables efficiently, with an average of around 20 days of payables outstanding. This means Catalyst Pharmaceuticals Inc takes approximately 20 days to pay its suppliers. The consistency in this metric suggests a stable relationship with its suppliers and effective management of working capital.

Overall, the activity ratios suggest that Catalyst Pharmaceuticals Inc is effectively managing its inventory, accounts receivable, and accounts payable, which are crucial components of working capital management.

Long-term

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Fixed asset turnover 333.23 293.75 251.83 199.60 252.90 217.41 185.89 166.18 146.85 140.42 138.84 127.27 915.95 793.16 712.86 604.03 487.17 515.48 282.34 92.49
Total asset turnover 0.85 0.84 0.68 0.63 0.57 0.58 0.64 0.62 0.59 0.60 0.61 0.61 0.62 0.68 0.91 1.01 0.91 0.75 0.53 0.21

Catalyst Pharmaceuticals Inc's fixed asset turnover has shown a generally increasing trend over the past few quarters, indicating that the company is generating more revenue from its fixed assets. This suggests better utilization and efficiency in utilizing its long-term assets to generate sales. However, the extremely high value for fixed asset turnover in the most recent quarter (Dec 31, 2023) may be an outlier and requires further investigation.

On the other hand, the total asset turnover ratio has fluctuated over the periods, with some quarters showing a higher turnover of total assets compared to others. Despite the variability, the overall trend indicates that Catalyst Pharmaceuticals Inc is generating revenue from its total assets at a relatively stable level.

Comparing the fixed asset turnover to the total asset turnover, it seems the company relies more on its fixed assets to generate sales compared to its total assets. This highlights the importance of effectively managing and utilizing fixed assets to drive revenue growth for Catalyst Pharmaceuticals Inc.